CDA | Evidence Driven
CDA | Evidence Driven

Cyramza for Advanced GC or GEJ Adenocarcinoma – Details

Details

Files
Generic Name:
Ramucirumab
Project Status:
Complete
Therapeutic Area:
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Cyramza
Project Line:
Reimbursement Review
Project Number:
PC0059-000
Performance Metric:
Achieved
Strength:
10 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Funding Request:
As a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma after prior chemotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Eli Lilly Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ramucirumab (Cyramza) GC or GEJ Adenocarcinoma - Final pERC Recommendation Final Recommendation View PDF
Ramucirumab (Cyramza) GC - Final Clinical Guidance Report Guidance Reports September 3, 2015 View PDF
Ramucirumab (Cyramza) GC - Final Economic Guidance Report Guidance Reports October 29, 2015 View PDF
Ramucirumab (Cyramza) GC - Initial pERC Recommendation Initial Recommendation September 3, 2015 View PDF
Ramucirumab (Cyramza) GC or GEJ Adenocarcinoma - PAG Feedback on Initial Recommendation Feedback October 29, 2015 View PDF
Ramucirumab (Cyramza) GC or GEJ Adenocarcinoma - Manufacturer (Eli Lilly Canada) Feedback on Initial Recommendation Feedback October 29, 2015 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 13, 2015